about
Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy modelsThe apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastomaHighly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.Role of GM-CSF signaling in cell-based tumor immunization.Immunotherapy of human cancers using gene modified T lymphocytes.Bacterial immunotherapy of gastrointestinal tumors.Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.Human melanoma-specific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo.Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes.Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospectsImmune cells in colorectal cancer: prognostic relevance and therapeutic strategies.Natural killer cells require selectins for suppression of subcutaneous tumorsIntravital imaging of CD8+ T cell function in cancer.Potential role of immunotherapy in advanced non-small-cell lung cancerTargeting the Fas/FasL signaling pathway in cancer therapy.Pharmacological Modulation of Proton Channel Hv1 in Cancer Therapy: Future Perspectives.IFN-gamma withdrawal after immunotherapy potentiates B16 melanoma invasion and metastasis by intensifying tumor integrin alphavbeta3 signaling.Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.GK-1 improves the immune response induced by bone marrow dendritic cells loaded with MAGE-AX in mice with melanoma.Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies.Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model.Effective nivolumab sequential thoracic radiotherapy in elderly patients with advanced squamous cell lung cancer: did radiation therapy play a role? A case report
P2860
Q24561405-7E4083C1-D1AA-4115-A626-DB8A31EE198DQ27027633-EBB61608-AA66-4F8E-A7EF-047C51E4CFCBQ28828457-A93DF399-FD3C-42C1-B907-CC3C168EDF89Q33436471-70C63194-758A-4CC2-A98A-F816494FE374Q33455830-B0823A21-6405-4542-8092-F1C3501F14DCQ34147010-10E89DEC-C227-4ACF-86A6-EEBD993AA1C2Q34188383-12F903DE-1E39-443D-97B1-8D2A52E62416Q34242204-6634EC41-0DA4-4E84-A153-2156AC1BE371Q34652570-07A8D15B-2F4C-4267-98C1-DDDA62599143Q35257907-FE62B01F-5A8C-4DA4-91D7-FC40BE7FFCC4Q35437978-F611E234-F7D9-42C7-BE21-FF75A6A8A69AQ35886450-B8DDD351-EA74-4F29-B6A9-4A9BA8227144Q36057468-D6022A40-C8CF-4513-A579-BF922CCA54F8Q36245682-F815A633-D38A-494A-8BD1-E0A43E0F6B46Q36449290-9DC62D45-9016-403E-A3AA-2AA011A88436Q36778827-6BA50F8E-5E8E-4536-A9B8-E5D8643F5EC3Q37134430-BFBF9B37-BEE0-4221-9B4E-B45431D44A8CQ37223426-E34DB7DE-3340-4077-A450-D969B4F3C435Q37229840-93601F57-E55F-4813-AF2F-108E0AD590F7Q37527869-197ACA1B-3D3E-4189-8C45-534A6824EACDQ37975245-B2002D69-C473-4A7E-B3F3-3083A4B62010Q38853680-53205A02-9D80-47B7-A8A5-CB606FCA81DFQ39319990-D10D8D9A-008D-4033-A181-1F2E75359AF4Q39445629-154E37C4-2701-40E4-9C47-61A07A2C1E4EQ41901253-16E2DDE6-A622-4ECF-AD12-4EE9A4D005FBQ42103777-D98B16C1-833E-4D3F-8ADE-EE6798A6BCE8Q45885829-3D8CC3B7-23CE-41D0-82AA-69E32848223DQ58797426-7C1DF76A-331F-4D11-A97D-26D63040501E
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
From cancer immunosurveillance to cancer immunotherapy.
@en
type
label
From cancer immunosurveillance to cancer immunotherapy.
@en
prefLabel
From cancer immunosurveillance to cancer immunotherapy.
@en
P2860
P1476
From cancer immunosurveillance to cancer immunotherapy.
@en
P2093
John Stagg
P2860
P304
P356
10.1111/J.1600-065X.2007.00566.X
P577
2007-12-01T00:00:00Z